Business Model Breakdown
How IO Biotech Inc Makes Money
IOBT
Market Cap
$3M
Employees
78
The Short Version
Prior to bankruptcy, IO Biotech Inc was a clinical-stage biopharmaceutical company focused on developing novel immuno-oncology therapies, specifically cancer vaccines, utilizing its proprietary T-win® platform. Its primary revenue generation model would have involved licensing agreements, milestone payments from partners, and eventual product sales if its lead candidates (like IO102-IO103) achieved regulatory approval. However, the company has ceased all operations due to Chapter 7 bankruptcy, rendering this business model defunct.
Where the Revenue Comes From
N/A (Historically, potential licensing fees and product sales upon approval)
Who buys: N/A (Historically, pharmaceutical partners and eventually healthcare providers/patients)
Why It Works (Competitive Advantages)
- ✔N/A
Economic Moat: None
What Our Analysis Says
DVR Score as of April 14, 2026
IO Biotech Inc (IOBTQ) has filed for Chapter 7 bankruptcy liquidation as of March 31, 2026, leading to a complete shutdown of operations and termination of all employees. This catastrophic event eliminates any future growth potential or financial viability. Common stockholders are explicitly stated to be 'unlikely to receive any distribution.' The previous analysis acknowledged significant financial fragility and the binary nature of drug development, but the ultimate negative outcome has materialized. Consequently, there is no investment potential, and the risk of total loss is now virtually guaranteed for current shareholders, rendering the company a 'dud' by all metrics. The score reflects this complete lack of future value.